Immunity to liver stage malaria: Considerations for vaccine design

Immunologic Research

Volumn 27, Issue 1, 2003, Pages 53-69

  Taylor Robinson, Andrew W ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antigens; Immunity; Liver stage; Malaria; Plasmodium; Vaccines

Indexed keywords

ANTIGEN; VACCINE;

CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; DRUG DESIGN; DRUG EFFICACY; HUMAN; IMMUNITY; LIVER; LIVER CELL; MALARIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, PROTOZOAN; HUMANS; LIVER; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM;

EID: 0037230928     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:27:1:53     Document Type: Review

References (110)

1. Engers HD, Godal T: Malaria vaccine development: current status. Parasitol Today 1998;14:56-64.
2. Ridley RG: Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002;415:686-693.
3. Taylor-Robinson AW: Immunoregulation of malarial infection: balancing the vices and virtues. Int J Parasitol 1998;28:135-148.
4. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al.: A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997;336:86-91.
5. Miller LH, Hoffman SL: Research toward vaccines against malaria. Nat Med 1998;4:520-524.
6. Hoffman SL, Franke E, Hollingdale MR, Druilhe P: Attacking the infected hepatocyte. In Malaria Vaccine Development. Hoffman SL, editor. American Society of Microbiology, Washington DC 1996;35-75.
7. Taylor-Robinson AW, Smith EC: A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection. Immunol Rev 1999;171:105-123.
8. Hollingdale MR, McCormick CJ, Heal KG, Taylor-Robinson AW, Reeve P, Boykins R, et al.: Biology of malarial liver stages: implications for vaccine design. Ann Trop Med Parasitol 1998;92:411-417.
9. Guérin-Marchand C, Druilhe P, Galey B, Londono A, Patarapotikul J, Beaudoin RL, et al.: A liver stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 1987;329:164-167.
10. Hollingdale MR, Leef JL, McCullough M, Beaudoin RL: In vitro culture of the exoerythrocytic stage of Plasmodium berghei from sporozoites. Science 1981;213:1021-1022.
11. Enserink M, Pennisi E: Researchers crack malaria genome. Science 2002;295:1207.
12. Rosenberg R, Wirtz RA, Schneider I, Burge R: An estimation of the number of sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg 1990;84:209-212.
13. Frevert U, Sinnis P, Cerami C, Shreffler W, Takacs B, Nussenzweig V: Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med 1993;177:1287-1298.
14. Müller HM, Reckmann I, Hollingdale MR, Bujard H, Robson KJ, Crisanti A: Thrombospondin-related anonymous protein of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells, suggesting a role for this molecule in sporozoite invasion of hepatocytes. EMBO J 1993;12:2881-2889.
15. Hollingdale MR, Sinden RE, van Pelt J: Sporozoite invasion. Nature 1993;362:26.
16. Meis JFGM, Verhave JP, Ponnudurai T, Hollingdale MR, Rijntjes JM, Sinden RE, et al.: Fine structure of the liver forms of the malaria parasite Plasmodium falciparum in human hepatocytes in vitro. Cell Tissue Res 1985;244:345-350.
17. Aikawa M, Schwartz AL, Uni S, Nussenzweig RS, Hollingdale MR: Ultrastructure of in vitro cultured exoerythrocytic stage of Plasmodium berghei in a hepatoma cell line. Am J Trop Med Hyg 1984;33:792-799.
18. Atkinson CT, Aley SB, Hollingdale MR, Aikawa M: Expression of Plasmodium berghei circumsporozoite protein on the surface of exoerythrocytic schizonts and merozoites. Am J Trop Med Hyg 1989;41:9-17.
19. Renia L, Mattei D, Gonna J, Pied S, Dubois P, Miltgen F, et al.: A malaria-heat-shock-like determinant expressed on the infected hepatocyte surface is a target of antibody-dependent cell-mediated cytotoxic mechanisms by non-parenchymal liver cells. Eur J Immunol 1990;20:1445-1449.
20. Krotoski WA, Garnham PCC, Cogswell FB, Collins WE, Bray RS, Gwadz RW, et al.: Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. Am J Trop Med Hyg 1986;35:263-274.
21. Sigler CL, Leland P, Hollingdale MR: In vitro infectivity of irradiated P. berghei sporozoites to cultured hepatoma cells. Am J Trop Med Hyg 1984;33:544-547.
22. Zhu J, Waters AP, Appiah A, McCutchan TF, Lal AA, Hollingdale MR: Stage-specific ribosomal RNA expression switched during sporozoite invasion of hepatocytes. J Biol Chem 1990;21:12,740-12,744.
23. Scheller LF, Azad AF: Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci USA 1995;92:4066-4068.
24. Zhu J, Hollingdale MR: Structure of Plasmodium falciparum liver stage antigen-1. Mol Biochem Parasitol 1991;48:223-226.
25. Fidock DA, Gras Masse H, Lepers JP Brahimi K, Ben Mohammed L, Mellouk S, et al.: Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 1994;153:190-204.
26. Hollingdale MR, Aikawa M, Atkinson CT, Ballou WR, Chen G, Li J, et al.: Non-CS pre-erythrocytic protective antigens. Immunol Lett 1990;25:71-76.
27. Terzakis JA, Vanderberg JP, Foley D, Shustak S: Exoerythrocytic merozoites of Plasmodium berghei in rat hepatic Kupffer cells. J Protozool 1979;26:385-389.
28. Good MF, Doolan DL: Immune effector mechanisms in malaria. Curr Opin Immunol 1999;11:412-419.
29. Doolan DL, Hoffman SL: The complexity of protective immunity against liver-stage malaria. J Immunol 2000;165:1453-1462.
30. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS: Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol 1984;132:909-913.
31. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M: Hybridoma produces antibodies directed against the sporozoite stage of malaria parasite. Science 1980;207:71-73.
32. Hoffman SL, Isenbarger D, Long G, Sedegah M, Szarfman A, Walters L, et al.: Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 1989;244:1078-1081.
33. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987;330:664-666.
34. Weiss WR, Berzofsky JA, Houghten RA, Sedegah M, Hollingdale MR, Hoffman SL: A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and P. berghei. J Immunol 1992;149:2103-2109.
35. Ferreira A, Schofield L, Enea V, Schellekens H, van der Meide P, Collins WE, et al.: Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 1986;232:881-884.
36. Maheshwari R, Czarniecki CW, Dutta GP, Puri SK, Dhawan BN, Friedman RM: Recombinant human gamma interferon inhibits simian malaria. Infect Immun 1986;53:628-630.
37. Mellouk S, Green SJ, Nacy CA, Hoffman SL: IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol 1991;146:3971-3976.
38. Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, et al.: Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon-γ and CD8+ T cells. J Exp Med 1994;180:353-358.
39. Sedegah M, Finkelman F, Hoffman SL: Interleukin-12 induction of interferon gamma-dependent protection against malaria. Vaccine 1994;91:10,700-10,702.
40. Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, et al.: Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med 1997;3:80-83.
41. Kun JFJ, Lell B, Lehman LG, Luckner D, Kremsner PG: Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 1998;351:265.
42. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370:650-652.
43. Renggli J, Hahne M, Matile H, Betschart B, Tschopp J, Corradin G: Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol 1997;19:145-148.
44. Baker MB, Podack ER, Levy RB: Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol Blood Marrow Transplant 1995;1:69-73.
45. Su Z, Stevenson MM: Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection. Infect Immun 2000;68:4399-4406.
46. Tsuji M, Miyahira Y, Nussenzweig RS, Aguet M, Reichel M, Zavala F: Development of antimalaria immunity in mice lacking IFN-gamma receptor. J Immunol 1995;154:5338-5344.
47. + cytotoxic T cell clone confers protection against murine malaria. J Exp Med 1990;172:1353-1357.
48. Calvo-Calle JM, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro ZR, Nardin EH: Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 1997;159:1362-1373.
49. Tsuji M, Mombaerts P, Lefrancois I, Nussenzweig RS, Zavala F, Tonegawa S: Gamma delta T cells contribute to immunity against the liver stages of mice in alpha beta T-cell-deficient mice. Proc Natl Acad Sci USA 1994;91:345-349.
50. McKenna KC, Tsuji M, Sarzotti M, Sacci JB, Witney AA, Azad AF: Gamma delta T cells are a component of early immunity against preerythrocytic malaria parasites. Infect Immun 2000;68:2224-2230.
51. Krzych U, Lyon J, Jareed T, Schneider I, Hollingdale MR, Gordon DM, et al.: T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage antigens. J Immunol 1995;155:4072-4077.
52. Good MF, Pombo D, Quakyi I, Riley EM, Houghten RA, Menon A, et al.: Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 1987;85:1199-1203.
53. Fidock DA, Gras-Masse H, Lepers JP, Brahimi K, Ben Mohamed L, Mellouk S, et al.: Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 1994;153:190-204.
54. + T lymphocytes is required for protective immunity against Plasmodium berghei. J Immunol 1996;156:3374-3381.
55. Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS: Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 1999;41:397-402.
56. Matzinger P: Tolerance, danger and the extended family. Annu Rev Immunol 1994;12:991-1045.
57. O'Farrelly C, Crispe IN: Prometheus through the looking glass: reflections on the hepatic immune system. Immunol Today 1999;20:394-398.
58. Rajan T: Why does Plasmodium have a pre-erythrocytic cycle. Parasitol Today 1997;13:284-286.
59. Khan ZM, Vanderberg JP: Eosinophil-rich, granulomatous inflammatory response to Plasmodium berghei hepatic schizonts in non-immunized rats is age-related. Am J Trop Med Hyg 1991;45:190-201.
60. Krżych U, Guebre-Xabier M, Schwenk R: Malaria and the liver: tolerance and immunity to attenuated plasmodia sporozoites. In T Lymphocytes in the Liver: Immunobiology, Pathology and Host Defense. Crisp IN, editor. Wiley-Liss, New York, 1999;163-195.
61. Faure P, Hukier E, Miltgen F, Renia L, Mazier D: Protective immunity against malaria: cellular changes in the liver vary according to the method of immunization. Parasite Immunol 1995;17:469-477.
62. Krzych U, Schwenk R, Guebre-Xabier M, Sun P, Palmer D, White K, et al.: The role of intrahepatic lymphocytes in mediating protective immunity induced by attenuated Plasmodium berghei sporozoites. Immunol Rev 2000;174:123-134.
63. + T cells persist in livers of mice protected against malaria by immunization with attenuated Plasmodium berghei sporozoites. Eur J Immunol 1999;29:3978-3986.
64. Crispe IN, Mehal WZ: Strange brew: T cells in the liver. Immunol Today 1996;17:522-525.
65. Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP: The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev 2000;174:47-62.
66. Scheller LF, Azad AF: Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci USA 1995;92:4066-4068.
67. + T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Immunol Lett 1995;46:199-205.
68. + T cell clones correlates with their levels of expression of adhesion molecules. J Exp Med 1991;175:895-905.
69. + T cells: A new family of T cells. Immunol Today 1996;17:71-76.
70. + αβ T cells with intermediary TCR induced in the liver of mice by IL-12. J Immunol 1995;154:4333-4340.
71. + T cells in the Plasmodium yoelii model. J Immunol 1999;163:884-892.
72. + effector function against intracellular infection. J Exp Med 1996;184:131-139.
73. + αβ T cells activated by IL-12 as a major inhibition of experimental tumor metastasis. J Immunol 1996;156:3366-3373.
74. Kaufman SHE: Immunity to intracellular bacteria. Annu Rev Immunol 1993;11:129-163.
75. + T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites. Cell Immunol 1997;180:143-152.
76. + TCR alpha beta intermediate cells increase during experimental malaria infection and are able to exhibit inhibitory activity against the parasite liver stage in vitro. J Immunol 2000;164:1463-1469.
77. Craddock TP, Zumla AM, Ollier WE, Chintu CZ, Muyinda GP, Lancaster FC, et al: Predominance of one T-cell antigen receptor BV haplotype in African populations. Immunogenetics 2000;51:231-237.
78. Hill AVS, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al.: Common west African HLA antigens are associated with protection from severe malaria. Nature 1991;352:595-600.
79. Hill AVS, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch F, et al.: Molecular analysis of HLA-disease association: HLA-B53 and resistance to severe malaria. Nature 1992;360:434-439.
80. Connelly M, King CL, Bucci K, Walters S, Genton B, Alpers MP, et al.: T cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guineain which malaria is holoendemic. Infect Immun 1997;65:5082-5087.
81. Bucci K, Kastens W, Hollingdale MR, Shankar A, Alpers MP, King CL, et al.: Influence of age and HLA type on IFN-γ responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1. Clin Exp Immunol 2000;122:94-100.
82. John CC, Sumba PO, Ouma JH, Nahlen BL, King CL, Kazura JW: Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya. Infect Immun 2000;68:5198-5204.
83. Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, et al.: Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 1999;179:980-988.
84. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG: HLA-DQB1* 0501-restricted Th1 type immune responses to Plasmodium falciparum liver stage antigen 1 protect against malaria anemia and reinfections. J Infect Dis 2001;183:168-172.
85. Kurtis JD, Lanar DE, Opollo M, Duffy PE: Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Infect Immun 1999;67:3424-3429.
86. Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, et al.: Parasite antigen-specific interleukin-10 and antibody responses predict accelerated parasite clearance in Plasmodium falciparum malaria. Eur Cytokine Netw 1998;9:639-646.
87. Domarle O, Migot-Nabias F, Mvoukani JL, Lu CY, Nabias R, Mayombo J, et al.: Factors influencing resistance to reinfection with Plasmodium falciparum. Am J Trop Med Hyg 1999;61:926-931.
88. Migot-Nabias F, Deloron P, Ringwald P, Dubois B, Mayombo J, Minh TN, et al.: Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. Trans R Soc Trop Med Hyg 2000;94:557-562.
89. + T cell epitope of Plasmodium falciparum. Immunity 1999;10:651-660.
90. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, et al.: Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-1893.
91. + T lymphocyte migration. J Immunol 1993;151:4545-4551.
92. Aidoo M, Lalvani A, Gilbert SC, Hu JT, Daubersies P. Hurt N, et al.: Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infect Immun 2000;68:227-232.
93. Hill AVS: Immunogenetics. Defence by diversity. Nature 1999;398:668-669.
94. Hill AVS: HIV and HLA: confusion or complexity? Nat Med 1996;2:395-396.
95. Sette A, Sidney J: Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999;50:201-212.
96. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, del Guercio M-F, et al.: Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 1996;45:79-93.
97. Carrington M, Nelson GW, Marlin MP Kissner T, Vlahov D, Goedert JJ, et al.: HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-1752.
98. Thursz MR, Thomas HC, Greenwood BM, Hill AVS: Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997;17:11-12.
99. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, et al.: Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998;177:1664-1673.
100. Aidoo M, Lalvani A, Allsopp CE, Plebanski M, Meisner SJ, Krausa P, et al.: Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995;345:1003-1007.
101. Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW: Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine 1999;18:251-258.
102. Brown WL, Mastico RA, Wu M, Heal KG, Simpson JC, Lord M, et al.: RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 2002;45:in press.
103. Sedegah M, Jones TR, Kaur M, Hedstrom R, Hobart P, Tine JA. et al.: Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998;95:7648-7653.
104. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, et al.: Enhancement of MHC class I restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16:439-445.
105. + T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 1999;18:623-632.
106. Yoshida S, Kashiwamura SI, Hosoya Y, Luo E, Matsuka H, Ishii A, et al.: Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite. Biochem Biophys Res Commun 2000;271:107-115.
107. Layton GT, Harris SJ, Myhan J, West D, Gotch F, Hill-Perkins M, et al.: Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology 1996;87:171-178.
108. Gilbert SC, Schneider J, Plebanski M, Hannah CM, Blanchard TJ, Smith GL, et al.: Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara: comparisons and combinations. Biol Chem 1999;380:299-303.
109. Plebanski M, Gilbert SC, Schneider J, Hannan CN, Layton G, Blanchard T, et al.: Protection from Plasmodium berghei infection by priming and boosting T cells to a single Class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998;28:4345-4355.
110. Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, Layton GT, et al.: A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997;12:1280-1284.